Drugs / realSKIN
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03695939 | Mar 2019 → Dec 2023 | mixed dermis disorder | XenoTherapeutics, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06223269 | May 2024 → Dec 2025 overdue | — | XenoTherapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | realSKIN | “realSKIN® is a live biotherapeutic, bi-layered, split-thickness, membranous, skin xenotransplant wound dressing manufactured from living porcine skin sourced from genetically...” NCT06223269 ↗ |
| Modality | Cell therapy | “Active Ingredient: Live (i.e. non-terminally sterilized) porcine cells, including endothelial cells of intact vasculature and those comprising the dermal and epidermal tissue layers” NCT03695939 ↗ |
| Route | Other | “Route of Administration: Surgical engraftment, via sutures or staples” NCT03695939 ↗ |